8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Mar 23, 2026·SEC
MIRA Pharmaceuticals, Inc.(MIRA)Earnings, Financials & Key Ratios
MIRA•NASDAQ
Price updated Jun 19, 2026
AboutMIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.Show more
- Revenue$0
- EBITDA-$10M-30.9%
- Net Income-$10M-33.0%
- EPS (Diluted)-1.35-164.7%
- ROE-165.87%+30.6%
MIRA Key Insights
MIRA Pharmaceuticals, Inc. (MIRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 173.7% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 53.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MIRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MIRA Price & Volume
MIRA Pharmaceuticals, Inc. (MIRA) stock price & volume — 10-year historical chart
Loading chart...
MIRA Growth Metrics
MIRA Pharmaceuticals, Inc. (MIRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-177.02%
Return on Capital
10 Years-370.82%
5 Years-370.82%
3 Years-284.03%
Last Year-166.67%
MIRA Peer Comparison
MIRA Pharmaceuticals, Inc. (MIRA) competitors in Clinical-stage biotech and oncology — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 SILO | 5.54M | 6.12 | -0.82 | -67.17% | -88.41% | |||
 LPCN | 12.69M | 2.33 | -1.38 | -82.35% | -5.71% | -66.69% | ||
 PSTV | 10.16M | 4.20 | -0.58 | -10.49% | -230.24% | -198.48% | 0.21 |
Compare MIRA vs Peers
MIRA Pharmaceuticals, Inc. (MIRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MIRA Income Statement
MIRA Pharmaceuticals, Inc. (MIRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - |
Operating Expenses | 67.63K | 2.15M | 7.05M | 8.53M | 8.02M | 10.49M | 9.79M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 52.98K | 770.12K | 2.99M | 6.5M | 4.71M | 8.77M | 7.86M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 14.65K | 684.45K | 2.35M | 1.57M | 3.31M | 1.72M | 1.93M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 697.6K | 1.7M | 453.55K | 0 | 0 | 0 |
Operating Income | -67.63K▲ 0% | -2.15M▼ 3082.3% | -7.05M▼ 227.5% | -8.53M▼ 21.0% | -8.02M▲ 6.0% | -10.49M▼ 30.9% | -9.79M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -3082.31% | -227.48% | -20.97% | 5.95% | -30.86% | - |
EBITDA | -67.63K | 0 | 0 | -8.53M | -8.02M | -10.49M | -9.79M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | 100% | - | - | 5.95% | -30.86% | -63.91% |
D&A (Non-Cash Add-back) | 0 | 2.15M | 7.05M | 0 | -2 | 0 | 0 |
EBIT | -67.63K | -2.15M | -7.05M | -8.53M | -8.02M | -10.49M | -9.79M |
Net Interest Income | -364 | -24.37K | -10.25K | -3.46M | -165.67K | 98.91K | 122.4K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 98.91K | 122.4K |
Interest Expense | 364 | 24.37K | 10.25K | 3.46M | 165.67K | 0 | 0 |
Other Income/Expense | -364 | -24.37K | -10.25K | -3.46M | 165.67K | 50.63K | -17.47K |
Pretax Income | -67.99K▲ 0% | -2.18M▼ 3101.1% | -7.06M▼ 224.3% | -11.98M▼ 69.8% | -7.85M▲ 34.5% | -10.44M▼ 33.0% | -9.81M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -67.99K▲ 0% | -2.18M▼ 3101.1% | -7.06M▼ 224.3% | -11.98M▼ 69.8% | -7.85M▲ 34.5% | -10.44M▼ 33.0% | -9.81M▲ 0% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -3101.12% | -224.29% | -69.77% | 34.46% | -32.98% | -23.87% |
Net Income (Continuing) | -67.99K | -2.18M | -7.06M | -11.98M | -7.85M | -10.44M | -9.81M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.00▲ 0% | -0.15▼ 3160.9% | -0.48▼ 220.0% | -0.65▼ 35.4% | -0.51▲ 21.5% | -1.35▼ 164.7% | -0.23▲ 0% |
EPS Growth % | - | - | -220% | -35.42% | 21.54% | -164.71% | -177.02% |
EPS (Basic) | -0.00 | -0.15 | -0.48 | -0.65 | -0.51 | -1.35 | - |
Diluted Shares Outstanding | 14.75M | 14.75M | 14.75M | 18.57M | 15.44M | 23.69M | 41.94M |
Basic Shares Outstanding | 14.75M | 14.75M | 14.75M | 18.57M | 15.44M | 23.69M | 41.94M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
MIRA Balance Sheet
MIRA Pharmaceuticals, Inc. (MIRA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 3.49K | 2.91M | 494.4K | 4.86M | 2.89M | 11.06M | 9.43M |
Cash & Short-Term Investments | 3.49K | 2.81M | 350.98K | 4.6M | 2.83M | 6.35M | 9.41M |
Cash Only | 3.49K | 2.81M | 350.98K | 4.6M | 2.83M | 6.35M | 4.82M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 4.59M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 0 | 100K | 143.43K | 11.86K | 0 | 4.71M | 21.75K |
Total Non-Current Assets | 18.88K | 445.61K | 363.67K | 74.21K | 35.44K | 35.44K | 35.44K |
Property, Plant & Equipment | 0 | 0 | 363.67K | 5.06K | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 35.44K | 0 | 35.44K |
Other Non-Current Assets | 18.88K | 445.61K | 0 | 69.15K | 0 | 35.44K | 35.44K |
Total Assets | 22.37K▲ 0% | 3.36M▲ 14897.8% | 858.07K▼ 74.4% | 4.93M▲ 474.8% | 2.92M▼ 40.7% | 11.09M▲ 279.5% | 9.46M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 14897.83% | -74.43% | 474.83% | -40.74% | 279.52% | 863.04% |
Total Current Liabilities | 90.36K | 1.09M | 1.37M | 558.1K | 723.35K | 702.07K | 114.76K |
Accounts Payable | 0 | 228.41K | 905.55K | 538.56K | 723.35K | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - |
Short-Term Debt | 90K | 293.06K | 133.06K | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 702.07K | 114.76K |
Current Ratio | 0.04x | 2.66x | 0.36x | 8.70x | 3.99x | 15.75x | 82.16x |
Quick Ratio | 0.04x | 2.66x | 0.36x | 8.70x | 3.99x | 15.75x | 82.16x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 84.27K | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 84.27K | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 90.36K | 1.09M | 1.45M | 558.1K | 723.35K | 702.07K | 114.76K |
Total Debt | 90K | 293.06K | 491.23K | 5.06K | 0 | 0 | 0 |
Net Debt | 86.51K | -2.52M | 140.25K | -4.6M | -2.83M | -6.35M | -4.82M |
Debt / Equity | - | 0.13x | - | 0.00x | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.49x |
Interest Coverage | -185.79x | -88.30x | -687.60x | -2.47x | -48.40x | - | - |
Total Equity | -67.99K▲ 0% | 2.26M▲ 3425.9% | -596.23K▼ 126.4% | 4.37M▲ 833.7% | 2.2M▼ 49.7% | 10.39M▲ 372.4% | 9.35M▲ 0% |
Equity Growth % | - | 3425.87% | -126.37% | 833.67% | -49.71% | 372.4% | 1031.72% |
Book Value per Share | -0.00 | 0.15 | -0.04 | 0.24 | 0.14 | 0.44 | 0.22 |
Total Shareholders' Equity | -67.99K | 2.26M | -596.23K | 4.37M | 2.2M | 10.39M | 9.35M |
Common Stock | 5.89K | 6.34K | 6.66K | 1.48K | 1.66K | 4.19K | 4.2K |
Retained Earnings | -67.99K | -2.24M | -9.3M | -21.29M | -29.14M | -39.58M | -40.73M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -5.89K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MIRA Cash Flow Statement
MIRA Pharmaceuticals, Inc. (MIRA) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -67.99K | -1.38M | -5.6M | -4.53M | -5.56M | -4.66M | -4.23M |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | -1923.97% | -307.28% | 19.13% | -22.69% | 16.17% | 111.31% |
Net Income | -67.99K | -2.18M | -7.06M | -11.98M | -7.85M | -10.44M | -9.81M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 0 | 0 | 1.3M | 2.55M | 1.92M | 6.31M | 5.44M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 24.37K | 10.25K | 5.54M | 0 | 35.21K | 234.38K |
Working Capital Changes | 0 | 776.01K | 146.58K | -639.69K | 371.25K | -567.56K | -96.81K |
Change in Receivables | 0 | 0 | 0 | -11.86K | 11.86K | 0 | -161.5K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | -389.52K | 184.78K | -594.15K | -117.44K |
Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 71.12K | 4.18M | 3.15M | 8.78M | 3.79M | 8.18M | 7.84M |
Debt Issued (Net) | 90K | 203.06K | -160K | 1.01M | 0 | 572.87K | 0 |
Equity Issued (Net) | 0 | 4.5M | 2.9M | 7.7M | 3.61M | 7.9M | -3.38K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -18.88K | -520.85K | 402.19K | 74.28K | 182.42K | -292.47K | 7.85M |
Net Change in Cash | 3.49K▲ 0% | 2.81M▲ 80279.9% | -2.46M▼ 187.6% | 4.25M▲ 272.9% | -1.77M▼ 141.6% | 3.51M▲ 298.6% | 3.61M▲ 0% |
Free Cash Flow | -67.99K▲ 0% | -1.38M▼ 1924.1% | -5.6M▼ 307.3% | -4.53M▲ 19.1% | -5.56M▼ 22.7% | -4.66M▲ 16.2% | -4.23M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | -1924.06% | -307.28% | 19.13% | -22.69% | 16.17% | 31.07% |
FCF per Share | -0.00 | -0.09 | -0.38 | -0.24 | -0.36 | -0.20 | -0.10 |
FCF Conversion (FCF/Net Income) | 1.00x | 0.63x | 0.79x | 0.38x | 0.71x | 0.45x | 0.43x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MIRA Key Ratios
MIRA Pharmaceuticals, Inc. (MIRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | -198.47% | -847.77% | -634.3% | -238.9% | -165.87% | -140.83% |
Return on Invested Capital (ROIC) | - | - | - | - | -461.38% | -220.43% |
Debt / Equity | 0.13x | - | 0.00x | - | - | 0.00x |
Interest Coverage | -88.30x | -687.60x | -2.47x | -48.40x | - | - |
FCF Conversion | 0.63x | 0.79x | 0.38x | 0.71x | 0.45x | 0.43x |
Related:MIRA Dividend History·MIRA Revenue History·MIRA Price History·MIRA P/E History·MIRA Financial Ratios·MIRA Institutional Holders
MIRA SEC Filings & Documents
MIRA Pharmaceuticals, Inc. (MIRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
MIRA Frequently Asked Questions
MIRA Pharmaceuticals, Inc. (MIRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MIRA Pharmaceuticals, Inc. (MIRA) grew revenue by 0.0% over the past year. Growth has been modest.
MIRA Pharmaceuticals, Inc. (MIRA) reported a net loss of $9.8M for fiscal year 2025.
Dividend & Returns
MIRA Pharmaceuticals, Inc. (MIRA) has a return on equity (ROE) of -165.9%. Negative ROE indicates the company is unprofitable.
MIRA Pharmaceuticals, Inc. (MIRA) had negative free cash flow of $4.2M in fiscal year 2025, likely due to heavy capital investments.